Skip to main content
. Author manuscript; available in PMC: 2013 Nov 3.
Published in final edited form as: Cancer Res. 2012 Mar 2;72(9):10.1158/0008-5472.CAN-11-2165. doi: 10.1158/0008-5472.CAN-11-2165

Figure 4. Gal-3 is necessary for Gal-3BP mediated IL-6 expression.

Figure 4

A. Immunocytofluorescence analysis of Gal-3 (red) and Gal-3 BP (green) in BMMSC treated with rGal-3BP (5 µg/ml), fixed without permeabilization as described in Materials and Methods. a to c. Untreated cells. d to f. Cells treated with rGal-3BP. B. Western blot analysis of cell – associated Gal-3 in BMMSC examined 72 hours after transfection with indicated siRNA as described in Materials and Methods. C. Amount of IL-6 produced over 24 hours by BMMSC Parallel transfected with siRNA as shown in B and incubated in the absence or presence of 5× CM from CHLA-255 cells or rGal-3BP (2.5 µg/ml). The data represent the mean IL-6 concentration (±SD) in the supernatant of triplicate samples and are representative of three independent experiments showing similar results. D. IL-6 Luciferase promoter activity in PC3 cells transfected with a Gal-3 siRNA and treated with rGal-3BP (5 µg/ml). The data represent the mean fold increase in the FLuc/RLuc from triplicate samples from 3 separate experiments.